Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cleveland Clinic Study Will Measure NSAID Safety In Heart Disease Patients

This article was originally published in The Tan Sheet

Executive Summary

The cardiovascular safety of ibuprofen, naproxen and celecoxib (Pfizer's Celebrex) will be compared in a worldwide clinical trial involving 20,000 patients, the Cleveland Clinic announced Dec. 13

You may also be interested in...

Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says

Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18

Pfizer Ad Says OTCs “Aren’t As Safe As You Might Think”

A new website from Pfizer touting the firm's COX-2 pain reliever Celebrex (celecoxib) questions the perceived safety profile of over-the-counter drugs

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts